USP <797> and compounded GLP-1 sterility: what it means for you
USP General Chapter <797> is the United States Pharmacopeia standard for sterile compounding. When a pharmacy prepares injectable semaglutide or tirzepatide, <797> governs how it must be done to keep the product sterile and safe. Here's why it matters when you choose a compounded GLP-1 provider.
What USP <797> actually covers
USP <797> describes the conditions and practices required to prevent harm — including microbial contamination, excessive bacterial endotoxins, and variability in strength — when compounding sterile preparations. For injectable GLP-1 medications, that means the pharmacy must control the air quality of the compounding environment (ISO-classified cleanrooms or containment devices), enforce rigorous hand hygiene and garbing, validate personnel technique, and assign beyond-use dates that reflect sterility risk.
The standard also mandates environmental monitoring — routinely testing surfaces and air for contamination — and documented cleaning. These are the invisible steps that separate a legitimate sterile-compounding operation from an unsafe one.
503A vs 503B: two regulatory paths
A 503A pharmacy compounds for an individual patient under a prescription and follows USP <797>. A 503B outsourcing facility registers with the FDA and follows the stricter Current Good Manufacturing Practice (CGMP) standards, which exceed <797>. Neither compounded product is FDA-approved, but both paths impose meaningful quality controls — and a provider that names a verifiable 503A or 503B partner is signaling it takes sterility seriously.
| Standard | Applies to | Oversight |
|---|---|---|
| USP <797> | 503A sterile compounding | State boards of pharmacy |
| CGMP | 503B outsourcing facilities | FDA registration + inspection |
| FDA approval | Brand Wegovy/Zepbound | Full FDA review (not compounded) |
What to ask a compounded GLP-1 provider
Before starting, confirm the pharmacy's name and whether it is a verifiable 503A or 503B facility, whether it performs third-party potency and sterility testing, and whether it will share a certificate of analysis. A provider that answers these plainly — and doesn't dodge sourcing questions — has cleared the bar that matters most for injectable safety.